1. Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di). (March 2023) Authors: Anolli, M.P.; Degasperi, E.; D'Offizi, G.; Brunetto, M.R.; Verucchi, G.; Federico, A.; Ciancio, A.; Mangia, A.; Santantonio, T.A.; Coppola, N.; Pellicelli, A.; Loglio, A.; Viganò, M.; Pileri, F.; Maracci, Monia; Puoti, M.; Piscaglia, F.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗